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Summary.-Leukaemia cells from the peripheral blood and bone marrow ofpatients
with acute myeloblastic leukaemia were labelled in vitro with [1251] 5-iodo-2'-deoxy-
uridine (IUdR). The myeloblasts were then injected into groups of mice and the
survival of these cells estimated by measuring isotope loss, using whole-body
counting. The isotope excretion from mice treated with various doses of cytosine
arabinoside (Ara-C) and those not treated with drugs were compared. This compari-
son showed that the sensitivity of myeloblasts to the drug varies from patient to
patient, and in one case was different for myeloblasts from bone marrow and from
blood from the same patient. We compare the clinical responses of myeloblasts to
Ara-C in 6 patients, who had high peripheral blood myeloblast counts, with the
sensitivities of their myeloblasts to Ara-C in mice. This comparison indicates that
the assay might be a useful way of predicting the response of leukaemic cells in
patients to cytotoxic agents.
MEASUREMENT of 1251 release from
[1251]5-iodo-2'-deoxyuridine (IUdR)-
labelled cells has been used to assess cell
survival in vivo in a number of animal
models (Hughes et al., 1964; Porteous and
Munro, 1972). In the previous paper in
this series (Falcao et al., 1977) we described
a technique for labelling both fresh and
cryopreserved human leukaemic myelo-
blasts with IUdR, and we investigated the
fate of the labelled cells after they had
been injected into mice. The present study
was undertaken to establish, in principle,
whether this technique can be used to
assess the susceptibility in vivo of human
leukaemic myeloblasts to chemotherapy.
PATIENTS
The patients studied had definite acute
myelobastic leukaemia. Brief clinical details
are given in the legends to figures. We are
extremely grateful to Drs C. Bunch, S.
Callender, C. Potter and Professor D.
Weatherall for allowing us to study their
patients. Five of the patients were treated
by low-dose cytosine arabinoside (Ara-C)
infusion as part of a pilot study being carried
out at Oxford by these workers. The rational
basis for this treatment and the reasons for
dose selection will be described elsewhere.
MATERIALS AND METHODS
Mycloblasts. Mycloblasts were collected
from thie peripheral blood or bone marrow.
Blood was anticoagulated with either acid
citrate, dextrose or heparin. Bone-marrow
aspirates were flushed into Medium RPMI
1640 containing heat-inactivated 10% foetal
bovine serum. Red blood cells and neutrophils
were removed from bone-marrow prepara-
tions by centrifugation through a Ficoll-
Triosil gradient of sp. gr. 1-080. Interface cells
were then washed in RPMI before being
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labelled. Myeloblasts from blood were separ-
ated from red cells by 1 g sedimentation
followed by one wash to remove platelets.
Preparations for labelling contained more
than 900o myeloblasts by morphiological
counting of Giemsa-stained films.
Labelling of myeloblasts.-A detailed
description of the way suitable conditions for
myeloblast labelling was established is given
in the preceding paper (Falciao et al., 1977).
RPMI 1640 containing 200 u/ml of penicillin,
100 ,ug/ml of streptomycin, fresh glutamine,
1O0/ pooled human AB serum (heated
previously at 56°C for 30 min) and 0-006
,uCi/ml of 125IUdR (Amersham, sp. act. 25-35
Ci/mmol) was used for labelling. Myeloblasts
were added to flat-bottomed glass culture
flasks at 0 7 x 106 cells/ml. The culture
medium was 1-1-5 cm deep in the flasks
during labelling, and the flasks were gassed
with 500 CO2: 95% air. Cultures were
incubated for 18-20 h at 37°C. The cells
were then centrifuged and washled twice in
Medium RPMI without serum supplement.
Animals.-CBA/He T6T6 or C3H mice
8-10 weeks old were used in this study.
Groups were matched for weight, and
animals were of the same strain and sex in
each experiment.
Labelling BP8 cells.-BP8 is a C3H-
derived fibrosarcoma which is maintained by
serial passage as an ascites tumour in C3H
mice. BP8 cells wsere removed from the
peritoneal cavity, washed twrice in RPMI
1640, counted and suspended at 2 x 105
cells/ml in RPMI with 125IUdR at 0 03
,uCi/ml. The mixture was incubated for 2 h at
37°C in an atmosphere of 50' co 2: 950% air.
The cells were then washed twice to remove
free label. The cells were then incubated for
a further 30 min at 37 °C, rew-ashed and
suspended at 107 cells/ml. Where killed
BP8 cells were to be injected, they weije
freeze-thawed 4 times. Both killed and viable
labelled BP8 were injected s.c. at 5 x 106/
mouse.
In vivo assay procedure.-Labelled myelo-
blasts were injected s.c. between the scapulae.
Each mouse was given 1-5 x 107 labelled
myeloblasts, the number of cells depending
on the amount of label incorporated bv them.
Whole-body 1251 was estimated each day at
about the same time, by counting the mice in
a large Nal well counter. Mice received 0 do
KI in their drinking water for 2 days before
myeloblast injection, and throughout the
durationi of each experiment, to block the
uptake of released 1251 by the thyroid. A
suspension of labelled myeloblasts in water
was counted at the same time as the mice, to
determine isotope decay and compensate for
fluctuations in counting efficiency. The
activity remaining at any time is expressed
as a percent of activity at the time of
injection of myeloblasts and is calculated:
percent radioactivity remaining at Day t
Counts Day t x (CountsstandardDay0)
(Counts standard Dayt) x 100
Counts Day 0
All countvs had background subtracted.
Results are expressed as thle geometric
mean ± loglo s.d. of the per cent radio-
activity remaining.
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Fic:. 1. The effect of Ara-C on the excietioIn
of 125I from mice injected with IUdR-
labelled and killed BP8 fibrosarcoma cells.
The cells were injected s.c. andl the drug
a(lministered i.v. 0, mice injecte(d with
Aia-C 24 h before the cells. A, mice
injecte(i with Ara-C immediately after the
injection of cells.
% inhibition of release=
% 1251 retained in %1251ietained iri
mice ieceiving (1rmg - mice receiving
arld killed cells killed cells only
100 x
% 1251 retained 0/O5I Ietainedl
in mice receiving - in mice receiving
live cells killed cells only
Groups of 3 mice were used. The 0
inhibition of 1251 release is calculated
from the geometric mean of the 00 1251
retained by the groups 24 h after the
injection of BP8.
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RESULTS
T'he effect of cytosine arabinoside on the
clearance of 125J by mice injected with
killed IUdR-labelled cells
This experiment was carried out using
125IUdR-labelled BP8 fibrosarcoma cells
which were killed by repeated freezing
and thawing before being injected s.c.
into mice. The results are shown in Fig. 1.
Ara-C was given i.v. at varying doses,
either immediately after or 24 h before,
the injection of cells.
When Ara-C was given immediately
after BP8 cells, there was no slowing in
the rate of 125J loss from mice. However,
100 or 200 mg Ara-C/m2, when given
24 h before the cells, caused a slowing in
the rate of 1251 elimination. By 48 h
after cell injection, 1251 retention was not
significantly different between treated
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and untreated mice. Similar results were
obtained when this experiment was re-
peated.
The effect of Ara-C' on the excretion of 125J
by mice injected with JUdR-labelled human
leuk-aemic myeloblasts
The results of these experiments are
given in Figs 2, 3 and 4.
In Fig. 2A and B, experiments are shown
where there was significant increase in the
rate of 1251 loss from Ara-C-treated mice.
The clinical details given in the legends
to figures indicate that these patients
showed a rapid response to Ara-C infusion.
However, the onset of acute marrow
necrosis in the patients whose myeloblasts
are represented in Fig. 2B complicates
evaluation of the drug sensitivity of his
myeloblasts.
Fig. 3A and B shownmveloblasts which
D A Y
FIG.S. 2, 3 an(l 4. 125I excretion from mice injected s.c. with 125IUdR-labelled human leukaemic
myeloblasts. The effect of an i.v. injection of Ara-C immediately after the injection of cells on 1251 excretion is assessed. Geometric means an(I logarithmic s.d. are shown for groups of 3-5 mice.
FiGo. 2A. This 37-5kg patient's blood myeloblasts were taken immediately before treatment. At this
stage she had 56 x 109 leukaernic myeloblasts per litre of blood. She was given 20 mg of Ara-C
per day by continuous i.v. infuision and by the 12th day the blood myeloblast count had fallen to I x 109/1. , no drug; , 200 mg Ara-C/m2. - 400 mg Ara-C/m2. Fit:. 2B. This 72-5kg patient presente(t with a blood myeloblast count of 63 x 109/1. Bone marrowN, aspiration at that time only yielded dark brown necrotic tissue at three sites. He was treated with continuous i.v. infusion ofAra-C 20 mg/day for 2 days and 80 mg/day for 5 days, before his bloodt myeloblast count fell to 1 x 1O9/I. Bloocd myeloblasts were studied immediately before tieatmenit. - no diug. 50mg/i2 Ara-C. .... - 100 mg/M2 Ara-C.
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FIG. 3A.-Blood myeloblasts were taken from this 65-kg patient immediately before treatment by
continuous i.v. infusion of Ara-C. After 28 days' infusion at 12 mg Ara-C/day, his blood
myeloblast count fell from 35 x 109 to 1 x 109/1. no drug. -* -* - 50 mg/M2
Ara-C. . = 100 mg/M2 Ara-C.
FIG. 3B and C.-Blood myeloblasts (Fig. 3B) and bone marrow myeloblasts (Fig. 3C) taken from this
92-kg patient immediately before treatment. This patient presented with 22 x 109 myelo-
blasts/l of blood and was treated by continuous i.v. infusion of Ara-C at 20mg/day for 2 days,
22 mg/day for 24 days and then 44 mg/M2 for 13 days before his bloodmyeloblast count fell to
1 x 109/1. = no drug. - - = 50 mg/m2/day. ..... ==100 mg/m2/day.
have a high spontaneous rate of JUdR
release. In each case, about 90% of
injected radioactivity is lost within 48 h.
This high rate of isotope release is prob-
ably due to rapid death of the labelled
cells. It is gratifying to see that despite
this, a significant cytotoxic effect of
Ara-C is demonstrable in mice, against the
myeloblasts of the patient depicted in
Fig. 3A. Fig. 3B and C indicate that
different characteristics may be seen in
myeloblasts from a single individual
taken from different sites. The marrow
myeloblasts from this patient represented
in Fig. 3C have a low rate of 125J loss,
and these cells appear sensitive to damage
by Ara-C. On the other hand the same
patient's peripheral blood myeloblasts
(Fig. 3B) show more rapid spontaneous
release ofisotope, and this is not increased
further by the administration of Ara-C.
We have compared marrow and blood
myeloblasts in 2 other patients. In these
patients the drug sensitivity and spon-
taneou srate ofisotoperelease didnotdiffer
between cells from the two sites. In all 3
patients the number of counts taken up
by marrow cells was greater than that by
blood cells.
Fig. 4 shows the rate ofexcretion of 125J
from mice injected with IUdR-labelled
myeloblasts from 2 further patients. The
spontaneous rate of isotope release is not
particularly high from the myeloblasts
from either patient, but in neither case
did Ara-C increase isotope release. The
clinical history of the response to Ara-C
in these 2 patients, which is given in the
legend to Fig. 3, shows that neither patient
was markedly sensitive to this drug.
DISCUSSION
Our results, although obtained in a
small group of patients, indicate that it is
feasible to measure the susceptibility of
leukaemic myeloblasts to lysis by chemo-
therapeutic agents, using an assay in which
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FIG. 4A.-Blood myeloblasts from this 70-kg patient were taken after the patient had received 7 5-
day courses of treatment in 13 weeks. Each course consisted of 95 mg ofrubidomycin i.v. on Day
1 and 120 mg of Ara-C i.v. on Days 1-5. The blasts were taken 3 days after the last course of
treatment, when the myeloblast count was rising. After an initial response to therapy this
patient showed progressive increase in resistance to these courses of treatment. The separate
lines represent geometric means of mice treated with no drug (-), 50 (-* -* -), 100 (. ) and
200 (-- -) mg-M/2 Ara-C.
FIG. 4B.-Results with labelled blood myeloblasts taken from a 42-kg patient before treatment by
continuous Ara-C infusion. These myeloblasts were cryopreserved over liquid N2 before being
rapidly thawed for labelling. Conditions of cryopreservation as in Falcao et al. (1977). The patient
presented with 32 x 109 myeloblasts/l of blood. She was treated by i.v. infusion of Ara-C at 10
mg/day for 5 days, 20 mg/day for 3 days, 40 mg/day for 9 days, and finally 80 mg/day for 11
days, before the blood myeloblast count fell below 1 x 109/1 on Day 27 of the infusion. No treat-
ment ( ) and 200 mg/M2 Ara-C ( - ).
cell death is assessed by 1251 excretion.
Such a result is in agreement with earlier
studies in which 125J elimination was used
to study the response of a murine leuk-
aemia to methotrexate (Hofer et at., 1969;
Hofer, 1972). Evaluation ofourresults was
facilitated by the fact that all the patients
studied had relatively high peripheral
myeloblast counts at presentation, and
that 5/6 patients described were treated
only with Ara-C.
The use ofthe thymidine analog, IUdR,
to label myeloblasts, means that the label
is only incorporated into cells actively
synthesizing DNA. The growth fraction of
myeloblasts is far from 100% (Crowther
et al., 1975) and so in this assay the
sensitivity is not being assessed for all
leukaemic cells from a patient. However,
21
this theoretical objection is to some extent
academic ifthe assay we describe is shown
to correlate consistently with the clinical
response to the drugs.
Myeloblasts die, as measured by 1251
excretion, 2-5 days after injection into
mice. This interval is sufficient to measure
the effect ofdrugs on myeloblast viability.
The relative contribution ofhost rejection
and spontaneous death of myeloblasts to
the rate of 125I loss is discussed in some
detail in our previous publication in this
issue (Falca-o et al., 1977).
The assay may be ofparticular value in
three contexts: intestingthe susceptibility
ofneoplastic cells to specific agents where
multiple drug therapy is contemplated;
in the selection of second-line drugs in
cases where primary therapy has failed;
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and finally in the preliminary investiga-
tion ofnew cytotoxic agents and schedules
for anti-leukaemic effect.
This study was supported in part by
the Cancer Research Campaign. S.T.S.
xvas supported by a Knox Memorial
Travelling Fellowship and R.F. by the
Fundacao Amparo Pesquisa Estado de
Sao Paulo.
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